- Home
- LTGO vs ABSI Comparison
LTGO vs ABSI Comparison
Compare LTGO & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTGO | ABSI |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 997.8M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LTGO | ABSI |
|---|---|---|
| Price | $21.97 | $8.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.96 |
| AVG Volume (30 Days) | 292.6K | ★ 2.7M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.22 | $2.24 |
| 52 Week High | $25.93 | $12.06 |
Technical Indicators
Market Signals| Indicator | LTGO | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 61.32 | 48.71 |
| Support Level | $18.46 | $8.55 |
| Resistance Level | $25.47 | $10.03 |
| Average True Range (ATR) | 1.87 | 0.60 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 46.72 | 29.04 |
Price Performance
Historical ComparisonAbout LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.